Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes

May 25, 2019Diabetes care

Blood Levels of Trimethylamine N-Oxide May Help Predict Heart and Kidney Problems in People with Type 1 Diabetes

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

In a study of 1,159 individuals with type 1 diabetes, higher plasma concentrations of trimethylamine N-oxide (TMAO) were linked to increased mortality and cardiovascular events.

After a median follow-up of 15 years, the study recorded 363 cases of all-cause mortality and 120 cases of cardiovascular mortality.
Higher TMAO levels were associated with significant increases in combined cardiovascular disease and coronary outcomes.
The association between TMAO and cardiovascular outcomes remained significant after adjusting for conventional risk factors, except for stroke and heart failure.
An inverse relationship was observed between TMAO levels and baseline kidney function, measured as estimated glomerular filtration rate (eGFR).
Further adjustment for baseline eGFR rendered the associations between TMAO and outcomes insignificant, suggesting TMAO may reflect renal function.

AI simplified

OBJECTIVE: Trimethylamine N-oxide (TMAO) is suggested as an independent gut microbiota-derived risk factor for cardiovascular and renal disease. We investigated associations between plasma TMAO concentrations and cardio-renal outcomes in a prospective study of individuals with type 1 diabetes.

RESEARCH DESIGN AND METHODS: Plasma TMAO was measured at baseline in 1,159 individuals with type 1 diabetes (58% male, mean ± SD age 46 ± 13 years). End points were all-cause and cardiovascular mortality, cardiovascular disease (CVD), and renal events tracked from national registries. Associations between TMAO and end points were tested using Cox regression models.

RESULTS: After 15.0 (6.7-19.3) (median [interquartile range]) years of follow-up, we recorded all-cause and cardiovascular mortality (= 363 and 120, respectively), combined CVD (= 406), coronary outcome (myocardial infarction and coronary intervention) (= 163), stroke (= 115), hospitalization for heart failure (= 81), and end-stage renal disease (= 144). In univariate analyses, higher TMAO concentrations were associated with all end points (≤ 0.005). Except for stroke and heart failure, all end points remained significantly associated with higher TMAO concentrations after adjustment for conventional cardiovascular risk factors (≤ 0.003). After further adjustment for baseline estimated glomerular filtration rate (eGFR), results became insignificant for all end points. TMAO was inversely associated with baseline eGFR (= 0.29;< 0.001). n n n n n n P P R P2

CONCLUSIONS: In individuals with type 1 diabetes, higher concentrations of plasma TMAO were associated with mortality, CVD events, and poor renal outcome, independent of conventional risk factors. However, the association became insignificant after further adjustment for baseline eGFR. This could reflect TMAO as a renal function marker or a risk factor for micro- and macrovascular complications mediated through impaired renal function.

Full Text

Full text is available at the source.

View full text ↗View full text (PDF) ↗

Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief